BLA 761458 · Glaxosmithkline LLC
Exdensur
Depemokimab-Ulaa
NovelCDER novel approval, Dec 16, 2025: To treat severe asthma characterized by an eosinophilic phenotype as an Komziftiadd-on maintenance therapy
Last checked: Nov 20, 2026Latest source record: Jun 10, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Dec 16, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
18
14 Phase 3, 8 recruiting
FAERS reports
79
31 serious, 4 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 10, 2026.
EXDENSUR is indicated for the add‑on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in adult and pediatric patients aged 12 years and older. Limitations of Use EXDENSUR is not indicated for the relief of acute bronchospasm or status asthmaticus [see Warnings and Precautions ( 5.2 )] . EXDENSUR is an interleukin‑5 (IL‑5) antagonist, a monoclonal antibody (humanized immunoglobulin G1 [IgG1] kappa) indicated for add‑on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in adult and pediatric patients aged 12 years and older. ( 1 ) Limitations of Use : Not for relief of acute bronchospasm or status asthmaticus. ( 1 )
Mechanism: Depemokimab‑ulaa is an IL‑5 antagonist (humanized IgG1 kappa monoclonal antibody), which binds to IL‑5 with a dissociation constant of 10.5 pM, inhibiting the bioactivity of IL‑5 with in vitro IC50 value of 4 pM by blocking its binding to the alpha chain of the IL‑5 receptor complex expressed on the cell surface. Depemokimab‑ulaa contains a triple amino acid substitution (YTE) in the fragment crystallizable (Fc) region which increases binding to the neonatal Fc receptor and thereby extends the elimination half‑life. These properties support the dosing interval of every 6 months. IL‑5 is the...
Therapeutic areas: Respiratory
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- EXDENSUR · DEPEMOKIMAB-ULAA 100MG · INJECTION, · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Depemokimab" as an intervention, any sponsor and status, largest first.
- A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic PhenotypePivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT04718389 · 1,717 participants · Start Jan 26, 2021 · Primary completion Sep 14, 2025
Drug: GSK3511294 (Depemokimab); Mepolizumab and 3 more · For: Asthma
Sites: Birmingham, Alabama; Scottsboro, Alabama; Litchfield Park, Arizona · 397 sites in all
- eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 InflammationPivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07177339 · 1,196 participants (planned) · Start Oct 20, 2025 · Primary completion Apr 2, 2029
Drug: Depemokimab; Placebo · For: Pulmonary Disease, Chronic Obstructive
Sites: Sheffield, Alabama; Tucson, Arizona; Escondido, California · 293 sites in all
- Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 InflammationPivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT06959095 · 981 participants (planned) · Start Jun 20, 2025 · Primary completion Dec 13, 2028
Drug: Depemokimab; Placebo · For: Pulmonary Disease, Chronic Obstructive
Sites: Bakersfield, California; Modesto, California; Newport Beach, California · 281 sites in all
- Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)Pivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT06961214 · 961 participants (planned) · Start Jun 23, 2025 · Primary completion Dec 13, 2028
Drug: Depemokimab; Placebo · For: Pulmonary Disease, Chronic Obstructive
Sites: Sheffield, Alabama; Aurora, Colorado; Brooksville, Florida · 193 sites in all
- An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT05243680 · 641 participants · Start Mar 1, 2022 · Primary completion May 19, 2025
Drug: GSK3511294 (Depemokimab) · For: Asthma
Sites: Mobile, Alabama; Lancaster, California; Colorado Springs, Colorado · 137 sites in all
- A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 AsthmaPivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07456033 · 456 participants (planned) · Start Mar 13, 2026 · Primary completion Sep 23, 2030
Drug: Depemokimab; Placebo · For: Asthma
Sites: Little Rock, Arkansas; Newport Beach, California; Aurora, Colorado · 17 sites in all
- A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic PhenotypePivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT04718103 · 397 participants · Start Feb 4, 2021 · Primary completion Apr 11, 2024
Drug: GSK3511294; Placebo · For: Asthma
Sites: Alabaster, Alabama; Mobile, Alabama; Phoenix, Arizona · 129 sites in all
- Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic PhenotypePivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT04719832 · 395 participants · Start Mar 17, 2021 · Primary completion Nov 21, 2023
Drug: GSK3511294 (Depemokimab); Placebo · For: Asthma
Sites: Encinitas, California; Long Beach, California; Pasadena, California · 123 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- asthma13
- chest pain6
- dizziness5
- dyspnoea5
- headache5
- cough4
- pruritus4
- rash4
- arthralgia3
- death3
- drug ineffective3
- fatigue3
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2023 | 12 |
| 2024 | 2 |
| 2026 | 65 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype.
Jackson DJ, Wechsler ME, Jackson DJ, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Switching to twice-yearly depemokimab from mepolizumab/benralizumab in severe asthma: a multicenter, randomized, double-blind, phase 3A clinical trial (NIMBLE).
Chupp G, Nagase H, Skowasch D, et al. · Am J Respir Crit Care Med 2026 · Multicenter Study, Randomized Controlled Trial
- Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials.
Gevaert P, Desrosiers M, Cornet M, et al. · Lancet 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Efficacy and safety of Depemokimab in asthma with eosinophilic phenotype: a systematic review and meta-analysis of randomized controlled trials.
Gill BA, Ijaz A, Fatima N, et al. · BMC Immunol 2025 · Systematic Review, Meta-Analysis
- Depemokimab reduces asthma exacerbations similarly to other biologics.
Bourdin A, Pavord ID, Ballew N, et al. · Ann Allergy Asthma Immunol 2026 · Systematic Review, Network Meta-Analysis
- Early and Sustained Efficacy of Depemokimab in Type 2 Asthma: A Pooled Analysis of the SWIFT-1/-2 Studies.
Wechsler ME, Pavord ID, Panettieri RA, et al. · J Allergy Clin Immunol Pract 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: GSK
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.